Get the Stockscreener App
39.11
1.04%
-0.41
Collegium Pharmaceutical Inc stock is traded at $39.11, with a volume of 447.83K.
It is down -1.04% in the last 24 hours and up +23.61% over the past month.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
See More
Previous Close:
$39.52
Open:
$39.84
24h Volume:
447.83K
Relative Volume:
1.43
Market Cap:
$1.23B
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
32.87
EPS:
1.19
Net Cash Flow:
$274.29M
1W Performance:
+3.63%
1M Performance:
+23.61%
6M Performance:
+34.26%
1Y Performance:
+8.52%
1-Day Range:
$38.81
$39.95
1-Week Range:
$37.29
$39.95
52-Week Range:
$23.23
$42.29
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
39.11 | 1.20B | 566.77M | 48.16M | 274.29M | 1.19 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Needham | Hold → Buy |
| Jul-30-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-07-24 | Upgrade | Jefferies | Hold → Buy |
| May-10-24 | Downgrade | Needham | Buy → Hold |
| May-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-25-23 | Reiterated | Needham | Buy |
| May-02-23 | Resumed | Jefferies | Buy |
| Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Jul-14-20 | Initiated | BWS Financial | Sell |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Feb-19-20 | Resumed | Jefferies | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-03-19 | Resumed | H.C. Wainwright | Buy |
| Apr-12-19 | Resumed | Janney | Buy |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Jan-16-19 | Reiterated | Needham | Buy |
| Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-18 | Reiterated | Needham | Buy |
| Dec-05-17 | Reiterated | Needham | Buy |
| Sep-11-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Reiterated | Needham | Buy |
| Sep-13-16 | Initiated | Gabelli & Co | Buy |
| Jun-01-15 | Initiated | Jefferies | Buy |
| Jun-01-15 | Initiated | Needham | Buy |
| Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
RSI Suggests Rebound May Be Near in Collegium Pharmaceutical Inc.July 2025 Big Picture & Growth Oriented Trade Recommendations - beatles.ru
Developing predictive dashboards with Collegium Pharmaceutical Inc. dataMarket Trend Review & Free Technical Confirmation Trade Alerts - Newser
What indicators show strength in Collegium Pharmaceutical Inc.July 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Will Collegium Pharmaceutical Inc. stock go up soon2025 Trading Recap & Low Risk High Reward Ideas - Newser
Collegium Pharmaceutical Inc. stock chart pattern explainedMarket Growth Summary & AI Forecast for Swing Trade Picks - Newser
Full technical analysis of Collegium Pharmaceutical Inc. stock2025 Investor Takeaways & Weekly Momentum Picks - Newser
What MACD signals say about Collegium Pharmaceutical Inc.Trade Risk Report & Free Long-Term Investment Growth Plans - Newser
Trend analysis for Collegium Pharmaceutical Inc. this week2025 EndofYear Setup & Daily Risk Controlled Trade Plans - Newser
Is Collegium Pharmaceutical Inc. stock poised for growthPortfolio Value Summary & High Conviction Investment Ideas - Newser
Collegium Pharmaceutical Inc. stock prediction for this weekPortfolio Risk Summary & Technical Entry and Exit Alerts - Newser
Is Collegium Pharmaceutical Inc. still worth holding after the dipEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Risk adjusted return profile for Collegium Pharmaceutical Inc. analyzedMarket Sentiment Summary & Fast Momentum Stock Entry Tips - Newser
Technical analysis overview for Collegium Pharmaceutical Inc. stockCPI Data & Free Community Supported Trade Ideas - Newser
Is this a good reentry point in Collegium Pharmaceutical Inc.Rate Hike & Weekly Setup with ROI Potential - Newser
Backtesting results for Collegium Pharmaceutical Inc. trading strategiesInsider Buying & Free Technical Pattern Based Buy Signals - Newser
Maryland State Retirement & Pension System Reduces Position in Collegium Pharmaceutical, Inc. $COLL - Defense World
Sector ETF performance correlation with Collegium Pharmaceutical Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - Newser
How to build a dashboard for Collegium Pharmaceutical Inc. stockWeekly Stock Recap & High Return Stock Watch Alerts - Newser
Rubric Capital Management Sells 25,000 Collegium Pharmaceutical Shares for $946,250 - AInvest
How to use a screener to detect Collegium Pharmaceutical Inc. breakoutsJuly 2025 Fed Impact & Free Long-Term Investment Growth Plans - Newser
Multi asset correlation models including Collegium Pharmaceutical Inc.Earnings Risk Report & Real-Time Volume Spike Alerts - Newser
What data driven models say about Collegium Pharmaceutical Inc.’s future2025 Key Highlights & Risk Controlled Stock Alerts - Newser
Can momentum traders help lift Collegium Pharmaceutical Inc.July 2025 Technicals & Verified Momentum Stock Alerts - Newser
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by HC Wainwright to "Strong-Buy" Rating - MarketBeat
Is Collegium Pharmaceutical's (COLL) Revenue Guidance and Buyback Balancing Short-Term Results With Long-Term Value? - simplywall.st
Major Shareholder Offloads Thousands of Collegium Pharmaceutical Shares! - TipRanks
Collegium pharma EVP Dreyer sells $184,880 in stock - Investing.com
Collegium pharma EVP Dreyer sells $184,880 in stock By Investing.com - Investing.com Australia
Collegium Pharmaceutical EVP Scott Dreyer Sells 4,861 Shares, Buys 4,861 at $38.03/Share. - AInvest
Have Collegium Pharmaceutical Insiders Been Selling Stock? - 富途牛牛
Published on: 2025-08-16 02:26:13 - thegnnews.com
We Think You Can Look Beyond Collegium Pharmaceutical's (NASDAQ:COLL) Lackluster Earnings - Yahoo Finance
How Collegium Pharmaceutical Inc. stock performs during market volatility2025 Trading Recap & Safe Capital Growth Plans - beatles.ru
Collegium Pharmaceutical Inc. Nearing Breakout Level After BounceJuly 2025 Gainers & Safe Entry Trade Reports - beatles.ru
The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call - Yahoo Finance
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” at HC Wainwright - Defense World
Can Collegium Pharmaceutical Inc. recover in the next quarterJuly 2025 Reactions & Safe Capital Growth Plans - Newser
Quant Tools Rank Collegium Pharmaceutical Inc. as High Risk High RewardEarnings Beat & Short-Term Trading Opportunity Alerts - newsyoung.net
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics - msn.com
Collegium Pharmaceutical Inc. Bounces Off Moving Average SupportQuarterly Trade Summary & Long Hold Capital Preservation Tips - sundaytimes.kr
Published on: 2025-08-13 16:47:11 - beatles.ru
IBD Rating Upgrades: Collegium Pharmaceutical Flashes Improved Relative Price Strength - MSN
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by HC Wainwright to Strong-Buy Rating - Defense World
3 Profitable Stocks We Think Twice About - Yahoo Finance
Collegium Pharmaceutical Q2 Earnings: Revenue Beats Estimates, Margin Pressure from Investments - AInvest
COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure - Yahoo Finance
Collegium Pharmaceutical Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
Collegium Pharmaceutical Earns Membership In 95-Plus Composite Rating Club - MSN
H.C. Wainwright assumes coverage on Collegium Pharmaceutical stock with Buy rating - Investing.com Canada
Collegium Pharmaceutical (COLL) Is Up 16.2% After Raising 2025 Revenue Guidance on Strong Q2 Results - simplywall.st
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Collegium Pharmaceutical Inc Stock (COLL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SANTINI GINO | Director |
Aug 15 '25 |
Sale |
37.19 |
5,405 |
201,018 |
95,042 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):